CYP19A1 and breast carcinoma: Last year, authors of the adjuvant denosumab (a monoclonal antibody that binds RANKL) in breast cancer trial (ABCSG-18) published no additional toxicity and a favorable safety profile of adjuvant denosumab therapy (60 mg subcutaneously biannually) among women with early breast cancer treated with aromatase inhibitors compared to the placebo group [27].